Rising Diabetes Prevalence in the Middle East and North Africa

By Melike Belenli Gümüş

November 20, 2024

A recent article from the World Health Organization (WHO) provides a comprehensive overview of the global diabetes epidemic, showcasing alarming trends, particularly in the Middle East and North Africa. The focus on the “rising diabetes rates” within these regions highlights the urgent need for intervention and policy changes to combat this health crisis.

Global Epidemiology and Estimates

The number of adults living with diabetes worldwide has surpassed 800 million, more than quadrupling since 1990. Global diabetes prevalence in adults rose from 7% to 14% between 1990 and 2022. By 2022, almost 450 million adults aged 30 and older – about 59% of all adults with diabetes – remained untreated, with a staggering 90% of these untreated individuals residing in low- and middle-income countries (LMICs).

Regional Focus: Middle East and North Africa

The article highlights regional trends related to rising diabetes rates in the Middle East and North Africa:

– The prevalence of diabetes among adults aged 18 and older is particularly concerning in certain areas. Although the exact statistics for the Middle East and North Africa are not specified, the article mentions that the WHO South-East Asia and Eastern Mediterranean Regions have some of the highest diabetes prevalence rates among adults aged 18 and older, around 20%.
– The Middle East and North Africa are projected to see an alarming 87% increase in the number of people with diabetes by 2045.

Burden of Diabetes

The treatment gap is a significant challenge in these regions. The article notes that the Eastern Mediterranean Region, which includes parts of the Middle East and North Africa, has one of the lowest rates of diabetes treatment coverage, with fewer than 4 in 10 adults with diabetes taking glucose-lowering medication.

The economic and health burden is substantial. Global health expenditure on diabetes was estimated at $966 billion in 2021 and is expected to reach $1 trillion by 2045, with a significant portion of this burden falling on LMICs, including those in the Middle East and North Africa.

Urgent Action Needed

The WHO emphasises the need for urgent action to combat rising diabetes rates and the widening treatment gaps, particularly in LMICs. This includes enacting policies that support healthy diets, physical activity, and improving health systems for prevention, early detection, and treatment.

In summary, the Middle East and North Africa regions are experiencing a significant rise in diabetes cases, with high prevalence rates and substantial treatment gaps. Addressing these issues through policy changes, improved health systems, and increased access to treatment is crucial to mitigate the growing burden of diabetes. Urging action on rising diabetes rates is necessary to improve health outcomes in these vulnerable areas.

Reference url

Recent Posts

lenacapavir HIV PrEP access
    

Global Health Partnerships Unite to Expand Access to Lenacapavir for HIV Prevention

💉 How can we ensure equitable access to HIV prevention methods like lenacapavir?

A recent initiative from the Global Fund, supported by key global health organizations, aims to provide affordable access to this new HIV pre-exposure prophylaxis medication.

With a goal to reach 2 million individuals over three years, this coordinated effort seeks to drastically cut HIV infections and align with our commitment to ending AIDS by 2030.

Explore the details of this impactful collaboration and how it could transform HIV prevention.

#SyenzaNews #globalhealth #HealthcareInnovation #MarketAccess

antimicrobial resistance africa
     

Africa’s Health Crisis: Antimicrobial Resistance and Mpox Outbreak

🌍 Are we prepared to tackle the hidden pandemic of antimicrobial resistance (AMR) in Africa?

With AMR rapidly becoming a dominant health crisis, it’s critical to understand its impact on our healthcare systems and most vulnerable populations.

The Africa CDC highlights the urgent need for substantial investment and coordinated responses to combat this escalating threat, alongside the ongoing Mpox outbreak.

Discover the pressing challenges and potential solutions in our latest article.

#SyenzaNews #GlobalHealth #HealthcareInnovation #AntimicrobialResistance #PublicHealth

BioSapien cancer drug delivery
    

BioSapien Innovative Cancer Drug Delivery Solutions

🌟 How is innovation in drug delivery shaping the future of cancer treatment? 🌟

Discover how UAE-based BioSapien is transforming the healthcare landscape with the MediChip™ platform, securing $5.5 million in pre-Series A funding to enhance cancer care.

This innovative solution promises to minimise side effects and improve treatment outcomes for patients, fully embracing the potential of biotechnology in the fight against cancer.

Read more about BioSapien’s journey and its impact on global health!

#SyenzaNews #biotechnology #oncology #innovation #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.